A game-changing technology for choice of medication in treatment of solid cancers based on screening of patient’s own live cancer cells.

There were 17 million new cases of cancer worldwide in 2018 and the number of new cases is expected to rise by about 70% over the next 20 years. According to “Europe against Cancer” data, in 2018, 3.9Mn new cases of cancer and over 1.9 million cancer deaths are estimated in Europe. These figures are also expected to rise due to Europe’s ageing population. The economic impact of cancer is significant and is increasing. Health expenditure on cancer increased continuously from €35.7 billion in 1995 to €83.2 billion in 2014 in the EU and spending on cancer drugs increased from €7.6 billion in 2005 to €19.1 billion in 2014. More than 80% of all cancers were caused by solid tumors that grow as a mass of cells in a particular organ, tissue or gland. Solid tumors make up about 30% of all cancers in children. 20% of solid cancers are rare and several of these have a huge unmet medical need for better treatment. Most of the solid tumors are treated through chemotherapy, radiotherapy, and/or surgery. However, at present, surgery is the most appropriate treatment option for cancer solid tumors. Chemotherapy is frequently used along with other types of solid tumor treatment i.e. surgery and radiation. The treatment course is influenced the health policy frameworks, state or insurance company budget and personal finances. Under these conditions, the drug's expected statistical treatment effect determines the choice of treatment. This is done with the understanding that a certain percentage of all patients will not have the effect of the medicine. Moreover, there is a danger of chemically induced shortened lifetime due to the medicine chosen. When the proposed method of expanding the fresh live tissue samples are successfully developed the system is ready for integration of -omics and CDSS in order to predict the optimal individual tailored cancer treatment.